Actionable insights straight to your inbox

Equities logo

Lyra Therapeutics Raises $29.5 Million Series B for Chronic Rhinosinusitis

Financing led by Perceptive Advisors to advance ear, nose and throat disease therapies (Image: Lyra Therapeutics).
Boston Scientific Corporation (BSX) has confounded the investment community in 2013, doubling in value and becoming the fifth best performing stock in the S&P 500 this year. The Natick,